Form 4 for DGX Quest Diagnostics
Accepted 2022-10-04 00:00:00 ET · period of report 2022-10-03 · accession 0001022079-22-000131 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-10-04 | 2022-10-03 | DGX | RING TIMOTHY M | Dir | M - OptEx | $61.23 | +2,000 | 25.9K | +8% | +$122.5K |
| D | 2022-10-04 | 2022-10-03 | DGX | RING TIMOTHY M | Dir | S - Sale+OE | $123.39 | -2,000 | 23.9K | -8% | -$246.8K |
| D | 2022-10-04 | 2022-10-03 | DGX | RING TIMOTHY M | Dir | M - OptEx | $61.23 | -2,000 | 260 | -88% | -$122.5K |
| D | 2022-10-04 | 2022-10-03 | DGX | RING TIMOTHY M | Dir | A - Grant | $0.00 | +333 | 12.7K | +3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-03 | M | A | 2,000 | $61.23 | 25,933 | D | — | — | |
| 2 | Common | Common Stock | 2022-10-03 | S | D | 2,000 | $123.39 | 23,933 | D | — | — | |
| 3 | Derivative | Stock Options (Right to Buy) | 2022-10-03 | M | D | 2,000 | $61.23 | 260 | D | $61.23 · — to 2023-05-21 | 2,000 Common Stock | (F2) The options vested in three annual installments beginning with the first on May 21, 2014, the second on May 21, 2015 and the final on May 21, 2016. |
| 4 | Derivative | Phantom Stock Units | 2022-10-03 | A | A | 333 | $0.00 | 12,748.35 | D | $0.00 · — to — | 333 Common Stock | (F4) Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. (F3) Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. |